

ESHO Annual Meeting
24 – 26 June 2015

Aarau and Zurich, Switzerland



WELCOME

The Kantonsspital Aarau (KSA) and the IT'IS Foundation for Research on Information Technologies in Society (IT'IS Foundation) are delighted to welcome you to Switzerland for the 30th annual meeting of the European Society for Hyperthermic Oncology – ESHO 2015 – the flagship event of the thermal cancer therapy community.

Although the use of heat as a healing tool has a long history, hyperthermia therapy in cancer continues to be classified as experimental, especially in the USA. For hyperthermia to become a more mainstream treatment option, progress is needed to expand understanding of the underlying biological mechanisms, to improve hardware and treatment planning software, and to design, implement, and interpret clinical trials.

Encouraging results from phase I, II, and III clinical trials support the position that hyperthermia in combination with radiotherapy and/or chemotherapy is a promising multimodality therapy for primary, recurrent, and metastatic cancers. According to Mark Dewhurst, «There is a tremendous amount of promise in hyperthermia as well as proof ...», based on largely positive findings from a wide range of studies.

ESHO 2015 convenes the clinicians, physicists, engineers, and biologists of the hyperthermia community to exchange and discuss new ideas and the latest research results. The meeting kicks off on the morning of June 24 with the educational day at the Kantonsspital Aarau, followed by a visit to the Animal Hospital in Zurich in the afternoon and the congress opening apéro at Technopark Zurich in the evening. The conference continues on June 25 – 26 at Technopark with plenary sessions on the biology and clinical applications of hyperthermia, and hyperthermia from physics and engineering perspectives, with emphasis on computational approaches to treatment planning and optimization. Be sure to attend the «Firing up Cancer» public event on the evening of June 25 and the 3-minute flash oral presentations delivered by young hyperthermia investigators in the mornings and afternoons of both days.

To quote Jens Overgaard, **the heat is (still) on!** here at ESHO 2015, where the international thermal cancer therapy community meets to map the bright future of hyperthermic radiation oncology!

Most Important Information

Emergency: 144
Police: 117
Technopark reception: 0041 44 445 10 00
Kantonsspital Aarau: 0041 62 838 27 00
Conference website: www.esho2015.org
Conference email: info@esho2015.org
Abstract book password: ESHO2015-abstracts
24.06: 8 SRO + 3 SSRPM credits
25-26.06: 8 SRO + 8 SSRPM credits per day

Venues

Kantonsspital Aarau	Technopark
Tellstrasse 25	Technoparkstrasse 1
5001 Aarau	8005 Zurich
Tel: 0041 62 838 27 00	Tel: 0041 44 445 10 00
www.ksa.ch	Email: info@technopark.ch
	www.technopark.ch

Organizers

IT'IS Foundation	Kantonsspital Aarau
Zeughausstrasse 43	Tellstrasse 25
8004 Zurich	5001 Aarau
Tel: 0041 44 245 96 86	Tel: 0041 62 838 27 00
Email: info@itis.ethz.ch	www.ksa.ch
www.itis.ethz.ch	

BOARD OF ESHO

President

G. van Rhoon, Erasmus Medical Center (NL)

Secretary / Treasurer

M. Horsman, Aarhus University (DK)

ESHO Board Members

S. Dall'Oglio, Verona University Hospital (IT)

V. Kouloulias,

National Technical University of Athens (GR)

L. Lindner, Munich University Clinic (DE)

O. Ott, University Clinic Erlangen (DE)

M. Persson, Chalmers University (SE)

T. ten Hagen, Erasmus Medical Center (NL)

G. van Tienhoven,

Academic Medical Center Amsterdam (NL)

CONGRESS COMMITTEE

Co-Chairs

S. Bodis, Kantonsspital Aarau

N. Kuster, IT'IS Foundation

Local Organizing Committee

P. Memminger, Kantonsspital Aarau

E. Jakubcaninova, IT'IS Foundation

D. Payne, IT'IS Foundation

LOCAL SCIENTIFIC COMMITTEE

S. Bodis, Kantonsspital Aarau

N. Datta, Kantonsspital Aarau

J. Fandino, Kantonsspital Aarau

G. Lutters, Kantonsspital Aarau

C. Mamot, Kantonsspital Aarau

D. Marder, Kantonsspital Aarau

E. Puric, Kantonsspital Aarau

O. Timm, Kantonsspital Aarau

S. Wyler, Kantonsspital Aarau

C. Caspar, Kantonsspital Baden

N. Hauser, Kantonsspital Baden

D. Zwahlen, Kantonsspital Chur

M. Guckenberger, University Hospital Zurich

M. Pruschy, University Hospital Zurich

E. Martin-Fiori, Children's Hospital Zurich

B. Werner, Children's Hospital Zurich

C. Rohrer-Bley,

University of Zurich Vetsuisse Faculty

R. Fuchslin,

University of Applied Sciences Zurich

S. Scheidegger,

University of Applied Sciences Zurich

M. Notter, Hopital La Chaux-de-Fond

R. Salomir, Geneva University Hospital

T. Lomax, Paul Scherrer Institute

R. Schneider, Paul Scherrer Institute

D. Weber, Paul Scherrer Institute

M. Capstick, IT'IS Foundation

N. Kuster, IT'IS Foundation

E. Neufeld, IT'IS Foundation

INVITED SPEAKERS

S. Bodis, Kantonsspital Aarau (CH)

J. Bourhis, Lausanne University Hospital (CH)

M. Capstick, IT'IS Foundation (CH)

A. Chaturvedi, Rajiv Gandhi Cancer Institute & Research Centre (IN)

H. Crezee,

Academic Medical Center Amsterdam (NL)

O. Dahl, University of Bergen (NO)

C. Dasenbrock, Fraunhofer ITEM Hannover (DE)

N. Datta, Kantonsspital Aarau (CH)

M. Dewhirst, Duke University (USA)

H. Dobsicek Trefna, Chalmers University (SE)

J. Fandino, Kantonsspital Aarau (CH)

U. Gaipl, University Clinic Erlangen (DE)

J. Hodler, University Hospital Zurich (CH)

M. Horsman, Aarhus University (DK)

H. Hofmann, Swiss Federal Institute of Technology Lausanne (CH)

R. Issels, Munich University Clinic & Helmholtz Center Munich (DE)

R. Kanaar, Erasmus Medical Center (NL)

S. Krishnan, The University of Texas MD Anderson Cancer Center (USA)

N. Kuster, IT'IS Foundation (CH)

L. Lindner, Munich University Clinic (DE)

E. Martin-Fiori, Children Hospital Zurich (CH)

A. Mortezaei, Zurich University Hospital (CH)

G. Multhoff, Helmholtz Center Munich (DE)

E. Neufeld, IT'IS Foundation (CH)

P. Niederer, Swiss Federal Institute of Technology Zurich (CH)

M. Notter, La Chaux-de-Fond Hospital (CH)

J. Overgaard, Aarhus University (DK)

O. Ott, University Clinic Erlangen (DE)

M. Paulides, Erasmus Medical Center (NL)

E. Puric, Kantonsspital Aarau (CH)

E. Repasky, Roswell Park Cancer Institute (USA)

C. Rohrer-Bley, University of Zurich Vetsuisse Faculty (CH)

R. Salomir, University Hospital Geneva (CH)

D. Speiser, University of Lausanne (CH)

J. Spiliotis, Metaxa Cancer Hospital (GR)

T. Szucs, University of Basel (CH)

T. ten Hagen, Erasmus Medical Center (NL)

J. van der Zee, Erasmus Medical Center (NL)

G. van Rhoon, Erasmus Medical Center (NL)

G. van Tienhoven,

Academic Medical Center Amsterdam (NL)

R. Wessalowski,

University Clinic Duesseldorf (DE)

L. Winter, Max-Delbrueck-Center for Molecular Medicine Berlin (DE)

ESHO 2015 – EDUCATIONAL DAY

Kantonsspital Aarau

Wednesday 24.06.2015

Session

Clinics

Chair: N. Datta

09:00 – 09:15

Clinical indications for superficial and deep hyperthermia. The ESHO recommendations
G. van Rhoon

09:15 – 09:30

Molecular insight of combined hyperthermia and radio-/chemotherapy
O. Dahl

09:30 – 09:45

Hyperthermia and immunomodulation
U. Gaipf

09:45 – 10:00

Reirradiation and hyperthermia in breast cancer; how to proceed
G. van Tienhoven

10:00 – 10:15

Progress in the treatment of gynaecological tumours
J. van der Zee

10:15 – 10:30

What did we learn from hyperthermia in rectal cancer?
O. Ott

10:30 – 11:15

Coffee Break & Practical Session

11:15 – 11:30

Guidelines for regional deep hyperthermia (RHT) in pediatric oncology
R. Wessalowski

11:30 – 11:45

Hardware and technology for radiofrequency hyperthermia
M. Capstick

11:45 – 12:00

How can we assure treatment quality and what is a good hyperthermia treatment?
H. Dobsicek Trefna

12:15 – 13:15

Swiss Hyperthermia Network Meeting (KSA)
E. Puric

ESHO 2015 – EDUCATIONAL DAY

Vetsuisse, Zurich

Wednesday 24.06.2015

12:15 – 14:00

Lunch & Bus Transfer

14:00 – 16:00

Visit to Vetsuisse, Zurich:
Hyperthermia treatment planning and workflow
M. Paulides
Guided Tour / Practical Presentation
C. Rohrer-Bley, M. Capstick

13:30 – 15:00

International Journal of Hyperthermia – Editorial Board Meeting (Technopark)

15:15 – 17:45

ESHO Board Meeting (Technopark)

18:00 – 20:00

Congress Opening & Aperó
G. van Rhoon, S. Bodis,
N. Kuster, J. Hodler, J. Overgaard

ESHO 2015 – CONFERENCE

Technopark Zurich

Thursday 25.06.2015

Session

Clinics

08:00 – 08:30

Hallmarks of hyperthermia R. Issels

Chair: M. Dewhirst, A. Chaturvedi

08:30 – 09:00

The future of biology in the field of hyperthermia M. Dewhirst

Chair: R. Issels, M. Dewhirst

09:00 – 09:30

MR-guided ultrasound-neurosurgery for the treatment of malignant brain tumors: feasibility and limitations J. Fandino

Chair: M. Dewhirst, R. Issels

09:30 – 10:00

Coffee Break

10:00 – 10:30

Focal therapy using high intensity focused ultrasound for the treatment of prostate cancer A. Mortezaei

Chair: A. Mortezaei, J. Fandino

10:30 – 11:00

Radiofrequency ablation: strategies for HCC and liver metastases A. Chaturvedi

Chair: A. Chaturvedi, J. Fandino

11:00 – 11:20

The role of HIPEC in the management of peritoneal surface malignancies J. Spiliotis

Chair: M. Dewhirst, H. Crezee

11:20 – 11:30

Paper I – Combination treatment of trans-arterial chemoembolization followed by radiotherapy with hyperthermia (CERT) in hepatocellular carcinoma with portal vein tumor thrombosis: interim analysis of prospective phase II trial H. Sahinbas

Chair: M. Dewhirst, H. Crezee

11:30 – 11:40

Paper II – Hyperthermia and proton irradiation in unresectable soft tissue sarcoma: first result from HYPROSAR study N. Datta

Chair: M. Dewhirst, H. Crezee

ESHO 2015 – CONFERENCE

Technopark Zurich

Thursday 25.06.2015

11:40 – 11:50

Paper III – A multicenter phase II study of radiotherapy (RT), hyperthermia (HT) and lyso-thermosensitive liposomal doxorubicin (LTLD, ThermoDox) in patients with loco-regional recurrent breast cancer

P. Gabriele

Chair: M. Dewhirst, H. Crezee

11:50 – 12:30

Debate: The time has not yet come to phase out hyperthermic oncology phase I and II trials *Pro: L. Lindner, Contra: N. Datta*

Chair: R. Issels

12:30 – 13:30

Lunch & Dr. Sennewald Medizintechnik GmbH Symposium

Session

Biology

13:30 – 14:00

The DNA damage response as a guide for precision anticancer therapy R. Kanaar

Chair: G. Multhoff, M. Horsman

14:00 – 14:30

Clinical implication of heat shock protein 70 (Hsp70) as a tumor biomarker G. Multhoff

Chair: R. Kanaar, M. Horsman

14:30 – 14:40

Paper I – A novel approach for thermal dosimetry S. Scheidegger

Chair: R. Kanaar, G. Multhoff

14:40 – 14:50

Paper II – Abscopal effect by modulated electro-hyperthermia N. Meggyeshazi

Chair: R. Kanaar, G. Multhoff

14:50 – 15:20

Coffee Break

15:20 – 15:50

Hyperthermia and immune based therapies against cancer D. Speiser

Chair: E. Repasky

ESHO 2015 – CONFERENCE

Technopark Zurich

Thursday 25.06.2015

15:50 – 16:20

Defining the role of the thermal microenvironment in regulation of lymphocyte activation and anti-tumor immunity E. Repasky

Chair: D. Speiser

16:20 – 16:40

Realistic biological approaches for improving thermoradiotherapy M. Horsman

Chair: D. Speiser, E. Repasky

16:40 – 17:00

Thermoradiotherapy planning: integration in routine clinical practice H. Crezee

Chair: D. Speiser, E. Repasky

17:00 – 17:10

Paper III – Hyperthermia: a targeted therapy in treating HPV-positive cervical carcinoma A. Oei

Chair: D. Speiser, E. Repasky

17:10 – 17:20

Paper IV – Hyperthermia of cancer spheroids using reduced graphene oxide nanocomposites as a model for deep tissue applications: a proof-of-concept J. Ramirez

Chair: D. Speiser, E. Repasky

17:20 – 17:40

Poster Flash Presentations

I Hyperthermia clinical and physical data: Italian community approach A. Di Dia

II Dose-finding and pharmacokinetic study of doxorubicin-containing thermosensitive phosphatidylglycerol-liposomes with regional hyperthermia in feline soft tissue sarcoma K. Troedson

III Time-temperature relationship of blistering during superficial hyperthermia A. Bakker

IV Serum levels of heat shock protein 70 in dogs and cats with cancer S. Dressel

Chair: S. Bodis, N. Datta

17:40 – 18:20

Debate: There is strong evidence to support that hyperthermia sensitizes cancer stem cells *Pro:* M. Horsman, *Contra:* J. Bourhis

Chair: J. Overgaard

18:30 – 20:00

Apero & Public Event

ESHO 2015 – CONFERENCE

Technopark Zurich

Friday 26.06.2015

Session

Physics & Nanotechnology

08:00 – 08:30

ZMT Zurich MedTech Workshop W. Wiedemair

08:30 – 09:00

Engineering and certification of iron oxide nanoparticles for hyperthermia H. Hofmann

Chair: S. Krishnan, T. ten Hagen

09:00 – 09:30

Nanoparticle-mediated hyperthermia S. Krishnan

Chair: T. ten Hagen, H. Hofmann

09:30 – 10:00

Coffee Break

10:00 – 10:20

Solid tumor chemotherapy through nanoparticle-mediated hyperthermia-triggered drug delivery T. ten Hagen

Chair: S. Krishnan, H. Hofmann

10:20 – 10:30

Paper I – Numerical analysis of amplitude modulation in magnetic nanoparticle hyperthermia F. Soetaert

Chair: S. Krishnan, T. ten Hagen

10:30 – 10:40

Paper II – Hyperthermia-mediated intravascular drug release from thermosensitive liposomes improves drug efficacy in models of human triple negative breast cancer M. Dunne

Chair: S. Krishnan, T. ten Hagen

10:40 – 10:50

Paper III – Thermosensitive liposomes encapsulating gemcitabine S. Limmer

Chair: S. Krishnan, T. ten Hagen

10:50 – 11:00

Paper IV – Hyperthermia and thermosensitive liposome treatments based on intravascular drug release, particle circulation and intratumoral accumulation W. Lokerse

Chair: S. Krishnan, T. ten Hagen

ESHO 2015 Lunch Symposium

Thursday, June 25, 2015
12:30 - 13:30 h,
Technopark Zurich, Switzerland

DR. SENNEWALD 
medizintechnik gmbh



Hyperthermia News from Pyrexar Medical

Chair: Mark Falkowski

Pyrexar Medical - Presentation of the new hyperthermia company

*Mark Falkowski
(Salt Lake City, USA)*

Pyrexar panel discussion Questions and answers

*with Mark Falkowski, Paul Turner,
Drew Wilkins, and Gerhard Sennewald*

First impressions on the performance of the new BSD2000-3D GE450W hybrid deep hyperthermia system

*Gerard van Rhoon PhD
(Rotterdam, The Netherlands)*

SigmaVision - an innovative software concept for MR temperature measurement

*Steffen Eisenhardt
(Munich, Germany)*

ESHO 2015 – CONFERENCE

Technopark Zurich

Friday 26.06.2015

11:00 – 11:20

Poster Flash Presentations

- I Improvement of existing thermosensitive liposomes encapsulating gemcitabine
B. Kneidl
- II Probing the thermal properties of magnetic nanoparticles by lock-in thermography
C. Monnier
- III New magnetic nanodevices for magneto-fluid hyperthermia applications
M.R. Ruggiero
- IV A promising green synthesis for magnetic nanoparticles leads to effective cancer treatment through versatile magnetic hyperthermia protocols
A. Makridis
- V Arranging at the nanoscale: effect on magnetic particle hyperthermia
E. Myrovali

Chair: E. Neufeld, N. Kuster

11:20 – 12:00

Debate: Is nanotechnology-based hyperthermia ready for clinical adoption?

Pro: S. Krishnan, *Contra:* C. Dasenbrock

Chair: H. Hofmann

12:00 – 12:30

General Assembly

12:30 – 13:30

Lunch & Poster Session

Session

Engineering

13:30 – 14:00

Modeling methodology and treatment planning for thermal therapy

E. Neufeld
Chair: M. Capstick, R. Salomir

14:00 – 14:10

Paper I – Design of an MRI compatible HYPERcollar3D for hyperthermia treatment of head and neck tumors

T. Drizdal
Chair: E. Neufeld, M. Capstick

14:10 – 14:20

Paper II – Image-guided RF phased array development

P. Turner
Chair: E. Neufeld, M. Capstick

ESHO 2015 – CONFERENCE

Technopark Zurich

Friday 26.06.2015

14:20 – 14:30

Paper III – HIFU hepatic tumor ablation: modeling of focusing and motion tracking approaches

E. Neufeld
Chair: M. Capstick, R. Salomir

14:30 – 14:50

Non invasive temperature monitoring for image-guided thermotherapies: a review of the state-of-the art

R. Salomir
Chair: E. Neufeld, L. Winter

14:50 – 15:20

Coffee Break

15:20 – 15:40

Non-invasive thermometry in hyperthermia

L. Winter
Chair: M. Capstick, E. Neufeld

15:40 – 15:50

Paper IV – Hyperthermia treatment planning and temperature optimization in childhood cancer

R. Wessalowski
Chair: R. Salomir, L. Winter

15:50 – 16:00

Paper V – Thermophysical fluid modelling for loco-regional hyperthermia treatment of non-muscle invasive bladder cancer

G. Schooneveldt
Chair: R. Salomir, L. Winter

16:00 – 16:20

Poster Flash Presentations

- I FLAMES: next generation Schottky diode sheet for quality assurance in hyperthermia
D. de Jong
- II Design of modular planar antenna for hyperthermia breast cancer treatment
O. Fiser
- III Hyperthermia applicator validation system with LED
I. Merunka
- IV Improvements in hyperthermia applicator design for heating head tumors
A. Takook
- V Simultaneous using of two superficial hyperthermia antennas: 3D-modeling and simulation
A. Di Dia

Chair: N. Kuster, M. Capstick

16:20 – 17:00

Highlight Papers

- I Early experience with the HYPERcollar3D applicator as radiosensitizer for tumors in head and neck region N. van Holthe
- II Tumor infiltrating lymphocytes are significantly associated with shorter survival of patients and grading in soft tissue tumors treated with hyperthermia T. Knoesel
- III The significance of tumor hypoxia and stroma on delivery of a heat-activated thermosensitive liposome formulation of cisplatin for treatment of cervical cancer Y. Dou
- IV MR-based reconstruction of *in vivo* electric conductivity values of cervical cancer patients E. Balidemaj

Chair: G. van Rhoon, S. Bodis

17:00 – 17:45

Debate: Positive clinical outcomes are not traceable to thermal physics

Pro: S. Bodis, *Contra:* G. van Rhoon

Chair: S. Krishnan, H. Hofmann

17:45 – 18:45

Awards, ESHO 2017 Announcement, & Closing Remarks

19:30 – 24:00

Social Dinner

- 1 N. Dengina Local hyperthermia combined with chemoradiotherapy in cervix cancer: complications and clinical response rate
- 2 E. Puric Deep-hyperthermia in treatment of muscle invasive bladder cancer for elderly patients: a single center's first experience
- 3 A. Oei PARP1-Inhibition sensitizes combined hyperthermia-radiation and combined hyperthermia-cDDP treatment of cervical carcinoma cells
- 4 J. Contreras Martinez Feasibility of local deep hyperthermia treatment in conjunction with standard cancer treatments and patterns of response
- 5 V. Lopresto CT-based characterization of *ex vivo* liver tissue undergoing microwave thermal ablation
- 6 S. Abdel-Rahman Effective heating of large superficial chest wall and axilla tumours with the Sigma-60 applicator
- 7 H. Sahinbas Clinical impact of stringent quality control in capacitative loco-regional hyperthermia
- 8 G. van Rhoon Inventory of hyperthermia related clinical trials as registered in ClinicalTrials.gov
- 9 N. Data A systematic review and meta-analysis for re-irradiation with hyperthermia for locoregional recurrent breast cancers
- 10 O. Szasz Specific effect of the amplitude modulation of the RF signal in modulated electrohyperthermia (mEHT) treatment in C26 allograft tumor model
- 11 C.C. Hsia Treatment of murine colon tumors using gold nanoparticles and localized hyperthermia
- 12 H. Chaachouay response and radioresistance of canine tumor cells *in vitro*
- 13 C. Maake Combined photodynamic therapy with microwave-based hyperthermia against cancer
- 14 D. Leeper Effects of hyperglycemia on lonidamine-induced acidification and de-energization of human melanoma xenografts
- 15 C.C. Chen Characterization of gold nanoparticle-based heat generation in response to different radiofrequency electric field
- 16 M. Paulides Heating capabilities of the novel HYPERcollar3D hyperthermia applicator: a simulation study
- 17 G. van Stam A fast and cost efficient technique to perform Quality Assurance measurements for superficial applicators
- 18 D. Vrba Metamaterial-applicator arrays for microwave hyperthermia treatments
- 19 H. Kok The influence of skin cooling during loco-regional hyperthermia on effective tumour heating
- 20 J. Hartmann ³T MR spectroscopy in different tissues for non-invasive thermometry
- 21 J. Müller Infrared based thermometry in local, superficial hyperthermia quality assurance
- 22 D. Marder Towards pre-treatment verification for hyperthermia treatment plans
- 23 E. Neufeld Modeling for correction and treatment envelope extension in transcranial focused ultrasound aberration



CE 0123




available in 2016

heckel-HT3000 Whole Body Hyperthermia with Water-filtered infrared-A Radiation


- Stimulation of antitumor immune response
- Enhancement of perfusion and drug delivery
- Fever-range and extreme WBH
- Oncological and non-oncological indications (esp. chronic inflammation and infection)

hydrosun-TWH 1500 Thermography-controlled Water-filtered infrared-A superficial Hyperthermia

- Contact-free heating
- Real-time thermography measurement and control of superficial temperatures
- Effective in combination with tolerable, reduced radiation doses even for large and heavily pretreated target areas



heckel medizintechnik | ++49 (0) 711-12 89 89-0 | info@heckel-medizintechnik.de | www.hyperthermie.de



WHEN MINDS LINK ...
INSIGHTS AND IDEAS
EXPAND TREATMENT
OPTIONS.



SPONSOR ACKNOWLEDGEMENTS

Platinum Sponsor



Gold Sponsor



Silver Sponsor



Bronze Sponsors




SPONSOR ACKNOWLEDGEMENTS



EXHIBITION FLOOR PLAN

EXHIBITOR LIST



- 1 Dr. Sennewald Medizintechnik GmbH
- 2 heckel medizintechnik GmbH
- 3 Celsius42+ GmbH
- 4 myTomorrows
- 5 Alba
- 6 Celsion
- 7 Oncotherm
- 8 Varian
- 9 Andromedics
- 10 ZMT Zurich MedTech AG
- 11 NanoTherics
- 12 ZHAW
- 13 CST
- 14 Taylor & Francis
- 15 Synchrotherm

- Exhibitor
- Food stand
- Standing table



SIEMENS

Today's well-being is tomorrow's greatest resource.

Siemens answers are creating an impact on human health that will last generations.


www.healthcare.siemens.ch

The healthier people are today, the better the world will be tomorrow. That's because long, healthy lives make it possible for people to give their best. And build a happier world for today's generations and generations to come. That's why Siemens works to advance human health, with answers that last. We're helping clinicians and hospitals expand access to care while cutting costs, so they can

better care for a growing world. We're creating innovations that will have a lasting impact, so an aging population can continue to be a healthy one. We believe that, like every precious resource on earth, human health should be cherished, sustained. Not just for today, but for the promise of a better tomorrow.

Answers for life.

HOW TO FIND QUAÏ 61



SYMPOSIA AND OTHER EVENTS

Various symposia and workshops will serve as opportunities for industrial partners and scientists from all disciplines to meet and discuss ideas, requirements, and novel products. To make this year's program especially riveting the organisers are also bringing together outstanding speakers from the clinician, the research, and the health economics community for a public event in form of a roundtable.

- | | |
|-------------|---|
| 24.06.2015 | Swiss Hyperthermia Network Meeting |
| 12:15–13:15 | Kantonsspital Aarau Haus 25, Rapportraum (1.UG) |
| 24.06.2015 | Vetsuisse visit and demonstration |
| 14:00–16:00 | Vetsuisse Zurich |
| 25.06.2015 | Industry Symposium |
| 12:30–13:30 | (Dr. Sennwald Medizintechnik GmbH)
Technopark Zurich |
| 25.06.2015 | Public Event |
| 18:30–20:00 | Technopark Zurich |
| 26.06.2015 | Industry Symposium |
| 08:00–08:30 | (ZMT Zurich MedTech AG)
Technopark Zurich |
| 26.06.2015 | ESHO General Assembly |
| 12:00–12:30 | |
| 26.06.2015 | Social Dinner |
| 19:30–24:00 | Quai 61 |

